Journal of LiverPub Date : 2016-07-07DOI: 10.4172/2167-0889.1000I102
L. Rodríguez-Fragoso
{"title":"Gallic Acid may have the Potential to Preventing the Development of Preneoplastic Lesions in Liver","authors":"L. Rodríguez-Fragoso","doi":"10.4172/2167-0889.1000I102","DOIUrl":"https://doi.org/10.4172/2167-0889.1000I102","url":null,"abstract":"Figure 1: Microscopic images show the potential chemopreventive effect of gallic acid. Preneoplastic lesions were developed in rats by administration of a single dose of DEN (200 mg/Kg i.p) and CCl4 (2 mL/kg i.p.) during two weeks. Preneoplastic lesions showed the presence of microscopical small-cell dysplastic focus characterized by loss of liver tissue architecture, changes in nuclear morphology, cellular pleomorphism and cell mitosis (arrows). The gallic acid (50 mg/kg p.o.) was given during five weeks previous to the induction of preneoplastic lesions. Animals pretreated with gallic acid maintained the morphological architecture of liver and no cells in mitosis were observed. In the last decades, several studies have shown the chemopreventive potential of different polyphenols in cancer [1]. Particularly, the gallic acid have shown possess several protective properties anti-cancer as anti-proliferative, pro-apoptotic and anti-tumorigenic effects in vitro and in vivo models [2]. Gallic acid has shown to have a significant chemopreventive effect on development of hepatic preneoplastic lesions in rats. Gallic acid maintains the organization of liver tissue and avoids the development of changes in nuclear morphology, reduces the cellular pleomorphism and the number of cells in mitosis (Figure 1).","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"29 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2016-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79478036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of LiverPub Date : 2016-06-21DOI: 10.4172/2167-0889.1000196
Rodriguez Fragoso, Alvarez Ayala, García Vazquez, J. ReyesEsparza
{"title":"Genistein Produces Hepatoprotection through Modulating EGFR Expression and Phosphorylation in Experimental Fibrosis","authors":"Rodriguez Fragoso, Alvarez Ayala, García Vazquez, J. ReyesEsparza","doi":"10.4172/2167-0889.1000196","DOIUrl":"https://doi.org/10.4172/2167-0889.1000196","url":null,"abstract":"Background and Objective: Liver disease chronicity leads to the appearance of fibrosis, cirrhosis, and eventually cancer. For this reason, it is important to research new fibrosis therapies. The use of genistein as a hepatoprotective agent has been studied, but its mechanism of action is unknown. The aim of this work was to evaluate the role of genistein as a fibrosis treatment and its possible mechanism of action through CCl4-induced inhibition of EGFR in rat specimens. Methods: Hepatic fibrosis was brought about by chronic administration of CCl4 to rats. Animals with fibrosis were treated with 1 mg/kg genistein. To evaluate the hepatoprotection of genistein on liver fibrosis, we made a histopathological analysis using both HE PCNA positive cells were reduced in this group. We observed liver functionality improvement in those animals with fibrosis that were treated with genistein. Conclusion: Genistein produces hepatoprotection through modulating the expression and phosphorylation of EGFR in experimental fibrosis.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"65 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2016-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85712925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Typical Presentation of Hepatocellular Carcinoma","authors":"Chakravarty Kd, Samantaray Sp, Vishwanath Rs, Shashikala, Kumar Acp","doi":"10.4172/2167-0889.1000199","DOIUrl":"https://doi.org/10.4172/2167-0889.1000199","url":null,"abstract":"Introduction: Hepatocellular carcinoma is commonly seen in chronic liver disease patients due to hepatitis B or C infection. Melena and haematemesis are the common gastrointestinal symptoms due to intraluminal haemorrhage. Surgical resection is the treatment of choice. Case presentation: We report a case of hepatocellular carcinoma presenting as gastric outlet obstruction in a 64 years male with chronic hepatitis B virus infection. Hepatocellular carcinoma was detected during evaluation for gastric outlet obstruction. Intra-operatively there was no invasion to the duodenum; rather there was extrinsic compression and adhesions around the duodenum. Patient underwent successful right posterior sectionectomy. Conclusion: Hepatocellular carcinoma presenting as gastric outlet obstruction is rare and curative surgery is possible in selected patients.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"40 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83817144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of LiverPub Date : 2016-05-20DOI: 10.4172/2167-0889.C1.006
Nada Eldomiaty
{"title":"Recurrence of hepatocellular carcinoma after living donor liver transplantation (single center experience)","authors":"Nada Eldomiaty","doi":"10.4172/2167-0889.C1.006","DOIUrl":"https://doi.org/10.4172/2167-0889.C1.006","url":null,"abstract":"D Liver Transplantation (DLT) started in 1995, using a donor liver with familial amyloid polyneuropathy (FAP), then increasing the pool of donors. Our Center started DLT in 2001; however cases of acquired amyloid neuropathy are increasingly being recognized following this procedure. Also our Center experience showed that the onset of FAP symptoms occurs earlier than expected. Several papers described clinical cases of acquired FAP developing 5 to 9 years after DLT. From 2001 to 2011 we have done 1078 liver transplants; we carried out 262 domino transplantations. All receptors transplanted between 2001 and 2011, were evaluated. All of them were observed and had clinical, histopathologic (salivary gland biopsy) and electrophysiologic evaluation. The symptomatic group started with sensory complaints involving their feet 4 to 10 years after DLT; three of those patients have been retransplanted to halt FAP progression and their clinical and paraclinical improvement is described. Five other patients are in the waiting list for retransplant. Patients with FAP acquired by transplantation are candidates for liver retransplantation to minimize the progression of symptoms. Liver retransplantation is considered to be a high-risk procedure but so far the results have been favorable.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76150333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of LiverPub Date : 2016-05-20DOI: 10.4172/2167-0889.1000I101
B. Sanei
{"title":"Portal Cavernoma as a Complication of Liver Hydatid Cyst","authors":"B. Sanei","doi":"10.4172/2167-0889.1000I101","DOIUrl":"https://doi.org/10.4172/2167-0889.1000I101","url":null,"abstract":"","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"8 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2016-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80383287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of LiverPub Date : 2016-03-07DOI: 10.4172/2167-0889.1000194
À. Escorsell, F. Torres, M. VegaCatalina, A. Mas, J. Ríos, M. Guevara
{"title":"Short-term Survival in Acutely Decompensated Cirrhotic Patients","authors":"À. Escorsell, F. Torres, M. VegaCatalina, A. Mas, J. Ríos, M. Guevara","doi":"10.4172/2167-0889.1000194","DOIUrl":"https://doi.org/10.4172/2167-0889.1000194","url":null,"abstract":"Aim: The present study was aimed at the early identification of the prognostic factors for 30-day mortality in acutely decompensated cirrhotic patients. Methods: Logistic regression models were used to study the predictors of mortality. Variables significant on univariate testing were included for the multivariate analysis. ROC curves were constructed. The model used retrospective data from 228 patients; and was prospectively validated among 64 patients from the Hospital Clinic: internal validation and 90 patients from Hospital Gregorio Maranon: external validation. Results: The model identified age at admission, serum concentrations of bilirubin, creatinine and sodium, and INR obtained 2 to 8 days after admission as predictors of death in this population. The resulting risk score was highly accurate: AUROC: 0.9150, 95%CI: 0.8509-0.9790 also in the internal and external validation series, but not better that the most widely used scores in hepatology: MELD: 0.8335, 95%CI: 0.7486-0.9184, MELD-Na: 0.8565, 95%CI: 0.7774-0.9356, iMELD: 0.8972, 95%CI: 0.8297-0.9648 and MESO Index: 0.8464, 95%CI: 0.7656-0.9272. The cutoff levels: LR+, LR- of the new score, MELD and MELD-Na that best predicted 30 days mortality were -0.09: 38.6, 0.51, 28: 16.7, 0.42 and 47: 12, 0.7, respectively. Conclusions: MELD, as well as new, more complicated and scanty used scores, obtained 2 to 8 days after admission allows the early and easy identification of patients with an acute decompensation of cirrhosis at high-risk of death on short-term follow-up. These scores may represent a useful tool to select the population suitable for studies to evaluate the efficacy of new therapies and stratify patients in randomized trials.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"1 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2016-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82195265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of LiverPub Date : 2016-02-11DOI: 10.4172/2167-0889.1000193
N. Majethia, M. Patil, A. Kalgutkar
{"title":"A Histo-Pathological Study of Liver in 118 Cases of Cirrhosis","authors":"N. Majethia, M. Patil, A. Kalgutkar","doi":"10.4172/2167-0889.1000193","DOIUrl":"https://doi.org/10.4172/2167-0889.1000193","url":null,"abstract":"The day has not arrived when predictive value of liver disease can be given like many laboratory tests. Autopsy studies provide us with useful baseline data to start a step towards achieving good morphological accuracy. The present study compromised of 118 cases of cirrhosis detected from the period January 2008 to December 2013. 3960 autopsies done during this period were scrutinized and 824 cases had liver pathology. Out of the 824 cases 118 had cirrhosis as the liver pathology, which makes incidence of cirrhosis at autopsy as 14.3% of all liver pathology, which shows a decreasing incidence of cirrhosis which may be due decrease in autopsy rate over the years, the reasons for the continuing decline are complex and include attitudes toward autopsies of hospital administrative staff, medical staff, and family members and also because of increase in diagnosis by liver biopsy and introduction of antifibrotic therapy.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"20 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2016-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89390399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of LiverPub Date : 2016-01-18DOI: 10.4172/2167-0889.1000191
Xiaohui Wang, Jiang-yan Liu, Gang Chen, Yu Li, Yumin Li
{"title":"Early Detection of Metastases by Bone Scintigraphy in Patients with Hepatocellular Carcinoma","authors":"Xiaohui Wang, Jiang-yan Liu, Gang Chen, Yu Li, Yumin Li","doi":"10.4172/2167-0889.1000191","DOIUrl":"https://doi.org/10.4172/2167-0889.1000191","url":null,"abstract":"Hepatocellular carcinoma (HCC) is relatively common worldwide. Until a few years ago skeletal involvement from HCC was rarely diagnosed. Thanks to novel imaging techniques and multidisciplinary treatment approaches, the overall survival in HCC patients has prolonged, and bone involvement has significantly increased currently. This short review summaries the value of bone scintigraphy in patients with hepatocellular carcinoma.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"111 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2016-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80421360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of LiverPub Date : 2016-01-01DOI: 10.4172/2167-0889.1000135
Pratika Y Hern, Alex, er Pedroza-Gonzalez, L. V. D. Laan, M. Hoogduijn, M. Peppelenbosch, Q. Pan
{"title":"Mesenchymal Stem/Stromal Cells Exert Trophic Effect on Colorectal Cancer Metastasis to the Liver","authors":"Pratika Y Hern, Alex, er Pedroza-Gonzalez, L. V. D. Laan, M. Hoogduijn, M. Peppelenbosch, Q. Pan","doi":"10.4172/2167-0889.1000135","DOIUrl":"https://doi.org/10.4172/2167-0889.1000135","url":null,"abstract":"Colorectal Cancer (CRC) is the third most common cancer in the world. CRC tends to metastasize to the liver, which may occur in 20% to 70% of patients and represents the major cause of death. Mesenchymal Stem/stromal cells (MSCs) have shown to be able to migrate to CRC site and play an important role in tumor progression. We have previously identified a resident MSC population in the liver. Therefore, this study aims to investigate whether there is infiltration of MSCs into patient CRC Liver Metastasis (CRC-LM) and their potential effects on tumor cell growth. By culturing resected patient CRC-LM tissue, we observed the emerging of fibroblast-like cells. Further phenotype and functional characterization confirmed their bonafide MSCs features. In situ staining with a well-established MSCs marker showed a significant enrichment of candidate MSCs in patient CRC-LM, particularly the tumor-stromal area. Moreover, MSCs secreted trophic factors significantly increased colony formation and growth of a metastatic CRC cell line. In summary, we found infiltration and enrichment of MSCs in CRC-LM patient, which could in turn nourish tumor cells.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"111 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79304764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of LiverPub Date : 2016-01-01DOI: 10.4172/2167-0889.1000138
A. Alizadeh, Mohammad-taghi Mohammad Khah, Navid Saadat damghani, R. Talaee, Hasan Rajabali Nia, Aazam Erfanifar
{"title":"Metabolic Syndrome in Patients with Gallstone","authors":"A. Alizadeh, Mohammad-taghi Mohammad Khah, Navid Saadat damghani, R. Talaee, Hasan Rajabali Nia, Aazam Erfanifar","doi":"10.4172/2167-0889.1000138","DOIUrl":"https://doi.org/10.4172/2167-0889.1000138","url":null,"abstract":"Background: Metabolic Syndrome (MetS) is defined as a cluster of multiple cardiovascular risk factors, including central obesity, elevated fasting plasma glucose, high blood pressure, dyslipidemia. The prevalence of MetS has been increasing gradually in the world and there are many hypotheses about relationship between metabolic syndrome and others diseases. The aim of this study is evaluation of prevalence of metabolic syndrome in the patients with gallstone disease. Methods and materials: 400 patients with gallstone disease entered in a cross sectional study. Medical files were extracted and metabolic syndrome was defined by Adult Treatment Panel III (ATP III) base on clinical data. Results: Metabolic syndrome was diagnosed in 213 (53.3%) subjects. In this group, 175 (82.2%) had their gallstone both in gall bladder and biliary tract and 38 (17.85) only in biliary tract. In patients without metabolic syndrome, 127 (67.9%) had the gallstone in both gallbladder and biliary tract and 60 (32.1%) only in their biliary tract. Comparison of these ratios led to a statistically significant difference (P=0.001; Odds Ratio: 2.18; CI 95%: 1.36-3.47). Conclusions: The results showed that may be a relationship between metabolic syndrome and gallstone disease. More future study with control group for this evaluation is necessary.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"18 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80984949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}